Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. Shockwave Medical aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). IVL is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes.

http://shockwavemedical.com/

Santa Clara

ShockWave Medical, Inc.

Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) has entered into a definitive agreement to acquire all outstanding shares of Shockwave Medical, Inc. (Nasdaq: SWAV) for $335.00 per share in cash, with a total enterprise value of approximately $13.1 billion. This acquisition will further extend Johnson & Johnson's position in the cardiovascular intervention market, providing an opportunity to accelerate their impact and drive greater value for patients, shareholders, and health systems. Shockwave's IVL technology for treating CAD and PAD, and its strong pipeline, are expected to enhance Johnson & Johnson's leadership position in medtech and expand into additional high-growth segments.

Johnson & Johnson completes acquisition of Shockwave Medical, Inc. to expand its presence in cardiovascular intervention

Johnson & Johnson completes acquisition of Shockwave Medical, Inc. to expand its presence in cardiovascular intervention

Company Info